Treosulfan-Based Conditioning for Bone Marrow Failure
Trial Summary
What is the purpose of this trial?
This trial tests if a combination of three drugs can reduce complications for patients with bone marrow failure diseases. The drugs work by killing harmful cells, stopping their growth, and reducing immune reactions.
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get specific guidance based on your situation.
What data supports the idea that Treosulfan-Based Conditioning for Bone Marrow Failure is an effective treatment?
The available research shows that Treosulfan-Based Conditioning is effective for treating bone marrow failure disorders. In a study with 14 patients who had various marrow failure disorders, all patients successfully received donor cells, and 13 out of 14 were alive with their diseases corrected after three years. This suggests that the treatment is effective in establishing donor cell acceptance with low side effects and good long-term outcomes. Compared to other treatments, Treosulfan-Based Conditioning has a lower risk of serious complications and high survival rates, making it a promising option for patients with marrow failure disorders.12345
What data supports the effectiveness of the drug combination of Treosulfan, Fludarabine, and Thymoglobulin for bone marrow failure?
Research shows that the combination of Treosulfan, Fludarabine, and Thymoglobulin is effective in establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and marrow failure disorders, with a high survival rate and low transplant-related mortality.12345
What safety data is available for Treosulfan-based conditioning in bone marrow failure treatment?
Treosulfan-based conditioning, often combined with fludarabine and thymoglobulin, has been studied for its safety and efficacy in hematopoietic cell transplantation. Studies show promising results with good engraftment and low toxicity. In a multicenter trial, 31 patients with nonmalignant diseases received treosulfan, fludarabine, and thymoglobulin, resulting in a 0% transplant-related mortality at day 100 and a 90% survival rate at 2 years. The combination was effective in establishing donor engraftment with low toxicity, although some patients experienced graft-versus-host disease (GVHD). The use of thymoglobulin was associated with a lower incidence of severe acute GVHD. These findings support the safety and potential of treosulfan-based conditioning for bone marrow failure treatment.12346
Is Treosulfan-based conditioning generally safe for humans?
Is the drug combination of Fludarabine, Thymoglobulin, and Treosulfan a promising treatment for bone marrow failure?
Yes, the combination of Fludarabine, Thymoglobulin, and Treosulfan is promising for treating bone marrow failure. It has shown to be effective in helping patients recover with low toxicity and high survival rates. This drug combination helps establish donor cells in the patient's body, which is crucial for recovery, and has a good safety profile.14578
How is the drug Treosulfan-based conditioning different from other treatments for bone marrow failure?
Treosulfan-based conditioning is unique because it combines treosulfan, fludarabine, and thymoglobulin to prepare patients for bone marrow transplants, offering a lower toxicity profile and improved survival rates compared to traditional myeloablative regimens. This combination is particularly effective for patients with nonmalignant diseases and marrow failure disorders, providing a safer alternative with reduced transplant-related mortality.14578
Research Team
Lauri Burroughs, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Margaret MacMillan, MD
Principal Investigator
University of Minnesota
Eligibility Criteria
This trial is for people aged 1 to under 50 with bone marrow failure diseases treatable by transplant, who have specific genetic mutations or meet diagnostic criteria. Excluded are those with certain other conditions, previous transplants, severe lung function impairment, liver issues, uncontrolled infections, HIV positive status or unwillingness to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning Regimen
Patients receive treosulfan, fludarabine, and rATG as part of the conditioning regimen before transplantation
Transplantation
Patients undergo bone marrow or peripheral blood stem cell transplant
GVHD Prophylaxis
Patients receive tacrolimus and methotrexate to prevent graft-versus-host disease
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Fludarabine
- Thymoglobulin (Rabbit Anti-thymocyte Globulin; rATG)
- Treosulfan
Fludarabine is already approved in European Union, United States, Canada for the following indications:
- Chronic lymphocytic leukemia
- Mantle-cell lymphoma
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Non-Hodgkin's lymphoma
- Stem Cell Transplant Conditioning
- Chronic lymphocytic leukemia
- Non-Hodgkin's lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Research Center
Lead Sponsor
Fred Hutchinson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
National Marrow Donor Program
Collaborator
Blood and Marrow Transplant Clinical Trials Network
Collaborator